IMFINZI 50 mg/mL concentrate for solution for infusion

DRUG4 trials

Sponsors

Fundacion GECP, AstraZeneca AB, Semmelweis University

Conditions

Biliary Tract CancerNon-Small cell lung cancer (NSCLC)bladder carcinomamalignant melanomanon small cell lung cancer (NSCLC)renal cell carcinomasmall cell lung cancer (SCLC)tumors of the head and neck region

Phase 1

A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants with Solid Tumours (IMFINZI-subQ)

Not yet recruitingCTIS2025-521639-34-00

AstraZeneca AB• Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

Target: 4Updated: 2026-03-27

Phase 2

Phase II randomized clinical trial for evaluating the safety and feasibility of fecal microbiota transplant (FMT) in stage II-III non-small cell lung cancer (NSCLC) patients, using immune checkpoint inhibitors (ICI) responders as donors. MIGRANT GECP 24/02

RecruitingCTIS2025-521251-24-00

Fundacion GECPNon-Small cell lung cancer (NSCLC)

Start: 2025-12-01Target: 68Updated: 2025-09-08

Phase 3

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

Not yet recruitingCTIS2025-523085-24-00

AstraZeneca ABBiliary Tract Cancer

Target: 27Updated: 2026-03-23

Phase 4

BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology

RecruitingCTIS2025-523620-44-02

Semmelweis Universitybladder carcinoma, malignant melanoma, non small cell lung cancer (NSCLC) +3

Start: 2026-01-20Target: 1000Updated: 2026-01-14